BioCryst Pharmaceuticals (NASDAQ:BCRX) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $20.00 price target on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at ($0.27) EPS. Other equities analysts have also […]
Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $20.00 price target on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at ($0.27) EPS. Other equities analysts have also […]
